Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals

Laura Gatti, Alexandra Sevko, Michelandrea de Cesare, Noemi Arrighetti, Giacomo Manenti, Emilio Ciusani, Paolo Verderio, Chiara M. Ciniselli, Denis Cominetti, Nives Carenini, Elisabetta Corna, Nadia Zaffaroni, Monica Rodolfo, Licia Rivoltini, Viktor Umansky, Paola Perego

Research output: Contribution to journalArticle

Abstract

Target-specific agents used in melanoma are not curative, and chemokines are being implicated in drug-resistance to target-specific agents. Thus, the use of conventional agents in rationale combinations may result in optimization of therapy. Because histone deacetylases participate in tumor development and progression, the combination of the pan-inhibitor SAHA and temozolomide might provide a therapeutic advantage. Here, we show synergism between the two drugs in mutant BRAF cell lines, in association with decreased phosphorylation of cell survival proteins (e.g., C-Jun-N-terminal-kinase, JNK). In the spontaneous ret transgenic mouse melanoma model, combination therapy produced a significant disease onset delay and down-regulation of Chemokine (C-C motif) ligand 2 (CCL2), JNK, and of Myeloid-derived suppressor cell recruitment. Co-incubation with a CCL2-blocking-antibody enhanced in vitro cell sensitivity to temozolomide. Conversely, recombinant CCL2 activated JNK in human tumor melanoma cells. In keeping with these results, the combination of a JNK-inhibitor with temozolomide was synergistic. By showing that down-regulation of CCL2-driven signals by SAHA and temozolomide via JNK contributes to reduce melanoma growth, we provide a rationale for the therapeutic advantage of the drug combination. This combination strategy may be effective because of interference both with tumor cell and tumor microenvironment.

Original languageEnglish
Pages (from-to)4516-4528
Number of pages13
JournalOncotarget
Volume5
Issue number12
Publication statusPublished - 2014

Keywords

  • CCL2
  • Histone deacetlylase inhibition
  • JNK
  • Melanoma
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals'. Together they form a unique fingerprint.

  • Cite this